Literature DB >> 4014571

Aortic and peripheral prosthetic graft infection: differential management and causes of mortality.

R A Yeager, D B McConnell, T M Sasaki, R M Vetto.   

Abstract

This report of 25 patients with prosthetic graft infection has compared the diagnosis, management, and outcome in 14 patients with infected aortic grafts with 11 patients with infected peripheral grafts (two axillofemorofemoral, five femorofemoral, five femoropopliteal, and one femoral interposition). Peripheral graft infection had a significantly shorter interval to diagnosis compared with aortic graft infection. Total graft removal combined with either autogenous revascularization or extraanatomic bypass using prosthetic graft was performed in all 14 patients with infected aortic grafts. Management of peripheral graft infection consisted of total graft removal in eight patients (four with autogenous revascularization and two with amputation) and partial graft removal in three patients (two with amputation). Mortality and amputation rates for infected aortic grafts were 43 percent and 25 percent, respectively compared with 36 percent and 27 percent for infected peripheral grafts. Recommendations for management of the infected aortic prosthetic graft include total graft removal, but methods and timing of revascularization are dependent on the specific features of the individual case. However, preferred management for the infected peripheral prosthetic graft includes total graft removal and, if indicated, revascularization using autogenous tissue.

Entities:  

Mesh:

Year:  1985        PMID: 4014571     DOI: 10.1016/0002-9610(85)90007-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

1.  False aneurysm of the axillary artery caused by graft infection: report of a case.

Authors:  K Yamamoto; T Yoshimura; S Ohtani
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  Percutaneous transluminal aortic angioplasty: early and late results.

Authors:  B Morag; A Garniek; A Bass; J Schneiderman; R Walden; Z J Rubinstein
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Jan-Feb       Impact factor: 2.740

Review 3.  [Possibilities for the use of 2nd generation cephalosporins in perioperative antibiotic prophylaxis].

Authors:  R Engemann
Journal:  Infection       Date:  1993       Impact factor: 3.553

4.  Management of infected vascular prostheses. The vascular homograft revisited.

Authors:  P Julia; V A Jebara; P Desgranges; P Dervanian; M de S Uva; C Acar; J N Fabiani
Journal:  Tex Heart Inst J       Date:  1991

5.  Selective preservation of infected prosthetic arterial grafts. Analysis of a 20-year experience with 120 extracavitary-infected grafts.

Authors:  K D Calligaro; F J Veith; M L Schwartz; J Goldsmith; R P Savarese; M J Dougherty; D A DeLaurentis
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

6.  Creation of a neo-aortoiliac system from lower extremity deep and superficial veins.

Authors:  G P Clagett; B L Bowers; M A Lopez-Viego; M B Rossi; R J Valentine; S I Myers; A Chervu
Journal:  Ann Surg       Date:  1993-09       Impact factor: 12.969

7.  Tolerability of High Doses of Daptomycin in the Treatment of Prosthetic Vascular Graft Infection: A Retrospective Study.

Authors:  Laurence Legout; Piervito D'Elia; Beatrice Sarraz-Bournet; Nicolas Ettahar; Stephan Haulon; Olivier Leroy; Eric Senneville
Journal:  Infect Dis Ther       Date:  2014-09-04

8.  Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin.

Authors:  Laurence Legout; Piervito Delia; Béatrice Sarraz-Bournet; Cécile Rouyer; Massongo Massongo; Michel Valette; Olivier Leroy; Stephan Haulon; Eric Senneville
Journal:  BMC Infect Dis       Date:  2014-04-28       Impact factor: 3.090

9.  Infected abdominal aortic grafts.

Authors:  M Y Al-Shehri; N V McPhail; G Barber; I Grillo; A A Softah
Journal:  Ann Saudi Med       Date:  1994-07       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.